Treatment with the LFPRLR SMO showed no effect on tumor Treg IL-10 or TGF-β1 content or cell surface CTLA-4 after 12 days of treatment, either as a proportion of CD4+ CD25+ Foxp3+ cells that expressed these molecules or the MFI for each (Fig. 5B-D). The gene discussed is FOXP3; the disease is neoplasm.